FDA approves Addyi for postmenopausal low libido

Show summary Hide summary

• What Addyi (flibanserin) does and how it works
• Why the FDA decision matters for postmenopausal women
• Evidence from clinical trials and expected benefits
• Safety profile: key risks and precautions
  • Who should avoid Addyi
• How doctors will assess candidates for treatment
• Patient experience, access, and real-world considerations
• The broader conversation: debate and context
• Questions to ask your clinician if you’re considering Addyi

The U.S. Food and Drug Administration has approved a change that could expand access to a controversial libido medication for a new group of patients. The move brings fresh attention to Addyi — the brand name for flibanserin — its benefits, risks, and what it might mean for women navigating sexual desire after menopause.

What Addyi (flibanserin) does and how it works

Addyi targets brain chemistry rather than hormones. It modulates serotonin and dopamine systems to influence sexual desire.

• Active ingredient: flibanserin, a serotonin 1A agonist and 2A antagonist.
• Administration: oral tablet taken daily at bedtime.
• Target condition: hypoactive sexual desire disorder (HSDD), characterized by low sexual desire and distress about it.

Why the FDA decision matters for postmenopausal women

This regulatory step broadens the labeled population for Addyi beyond its initial approval. For many women, low desire emerges or persists after menopause.

• It gives clinicians an additional pharmacologic option.
• Women who previously did not qualify based on age may now be eligible.
• Insurance coverage patterns could shift if payers adopt the new label.

Evidence from clinical trials and expected benefits

Clinical studies that supported the decision measured changes in desire and associated distress.

• Trials reported modest increases in sexual desire scores over placebo.
• Benefits were generally described as small to moderate in magnitude.
• Improvements were assessed using validated questionnaires and patient-reported outcomes.

Not every patient will experience meaningful benefit. Treatment decisions should be personalized and consider expectations.

Safety profile: key risks and precautions

Safety has been central to debates about flibanserin. The drug carries specific warnings that affect who can use it safely.

• Dizziness and sleepiness: common, which is why dosing at bedtime is recommended.
• Hypotension and syncope: risk increases with alcohol and certain medications.
• Drug interactions: strong CYP3A4 inhibitors raise flibanserin levels and require avoidance.
• Not for use with alcohol: concomitant alcohol use has been linked to severe hypotension and fainting.

Prescribers must review a patient’s medication list and alcohol use before initiating therapy.

Who should avoid Addyi

• Women taking strong CYP3A4 inhibitors.
• Those with significant liver impairment.
• People who cannot follow nightly dosing or who consume alcohol regularly.

How doctors will assess candidates for treatment

Clinicians will evaluate medical history, menopause status, and mental health before prescribing.

1. Confirm that low desire causes distress and is not due to other medical or psychiatric conditions.
2. Review possible contributing medications and substance use.
3. Discuss realistic expectations and nonpharmacologic options.

Shared decision-making is critical. Patients and providers should weigh benefit versus risk together.

Patient experience, access, and real-world considerations

Availability may change how postmenopausal women view treatment for sexual concerns.

• Some women report meaningful gains in intimacy and satisfaction.
• Others find side effects outweigh benefits or see little change.
• Cost and insurance coverage will shape uptake.

The broader conversation: debate and context

Addyi’s approval history has been contentious, with advocates and critics voicing different priorities.

• Supporters emphasize unmet needs and patient-reported distress.
• Critics point to modest efficacy and safety risks.
• Regulators have previously required risk-management measures to reduce harm.

This new approval revives questions about how to balance access, advertising, and informed consent.

Questions to ask your clinician if you’re considering Addyi

• Am I an appropriate candidate for flibanserin?
• What benefits can I realistically expect?
• How will you monitor for side effects?
• Are there alternatives I should try first?